EAST-AFNET 4: Early Rhythm Control in AF Gains New Life medscape.com/viewarticle/93…
As compared to AFFRIM trial:
1/1 This study incorporated AF ablation as an option in the rhythm control strategy, & treatment started soon after diagnosis of AF
1/1 This study incorporated AF ablation as an option in the rhythm control strategy, & treatment started soon after diagnosis of AF
2/2
About 40% of patients had their first AF episode at the time of randomization, & the median time from diagnosis to randomization was just 36 days.
About 40% of patients had their first AF episode at the time of randomization, & the median time from diagnosis to randomization was just 36 days.
3/6
- Also most of the CVS complications occur during first year of AF and early treatment would have led to lower complications due to AF.
- Also most of the CVS complications occur during first year of AF and early treatment would have led to lower complications due to AF.
4/6
About 8% in rhythm control went for AF ablation. Whether this led to good outcomes?
About 8% in rhythm control went for AF ablation. Whether this led to good outcomes?
5/6
- The commonest drug used in this trial for rhythm control was Flecainide (36%), followed by amiodarone and dronedarone
- The commonest drug used in this trial for rhythm control was Flecainide (36%), followed by amiodarone and dronedarone
6/6 In India - Flecaindie is sparingly used by Physicans. One reason could be that we see a major chunk of AF due to SHD
Rhythm control is beneficial, especially in early AF. EAST trial provide strong evidence for this hot debate about rate vs rhythm control in AF. Never shy to offer AF ablation in appropriate selective patients 👍
